Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Share Class Description:
WBO:REGN: Ordinary SharesCompare
Compare
Traded in other countries / regions
REGN.USA0R2M.UKREGN34.BrazilREGN.MexicoRGO.Germany1REGN.ItalyREGN.Austria IPO Date
2017-05-22Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.62 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.49 | |||||
| Interest Coverage | 64.93 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.6 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16 | |||||
| 3-Year EBITDA Growth Rate | 5 | |||||
| 3-Year EPS without NRI Growth Rate | 7.9 | |||||
| 3-Year FCF Growth Rate | 22.8 | |||||
| 3-Year Book Growth Rate | 32.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.54 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.11 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.68 | |||||
| 9-Day RSI | 29.34 | |||||
| 14-Day RSI | 26.3 | |||||
| 6-1 Month Momentum % | -4.8 | |||||
| 12-1 Month Momentum % | 18.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | |||||
| Quick Ratio | 4.46 | |||||
| Cash Ratio | 2.68 | |||||
| Days Inventory | 522.18 | |||||
| Days Sales Outstanding | 149.18 | |||||
| Days Payable | 109.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 2 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.12 | |||||
| Operating Margin % | 29.54 | |||||
| Net Margin % | 33.61 | |||||
| FCF Margin % | 23.9 | |||||
| ROE % | 17.19 | |||||
| ROA % | 13.44 | |||||
| ROIC % | 17.89 | |||||
| ROC (Joel Greenblatt) % | 52.57 | |||||
| ROCE % | 16.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.68 | |||||
| Forward PE Ratio | 17.32 | |||||
| PE Ratio without NRI | 17.37 | |||||
| Shiller PE Ratio | 24.43 | |||||
| Price-to-Owner-Earnings | 28.97 | |||||
| PEG Ratio | 0.98 | |||||
| PS Ratio | 6.28 | |||||
| PB Ratio | 2.83 | |||||
| Price-to-Tangible-Book | 2.95 | |||||
| Price-to-Free-Cash-Flow | 26.18 | |||||
| Price-to-Operating-Cash-Flow | 20.45 | |||||
| EV-to-EBIT | 15.07 | |||||
| EV-to-Forward-EBIT | 14.88 | |||||
| EV-to-EBITDA | 13.79 | |||||
| EV-to-Forward-EBITDA | 13.86 | |||||
| EV-to-Revenue | 5.48 | |||||
| EV-to-Forward-Revenue | 5.11 | |||||
| EV-to-FCF | 22.85 | |||||
| Price-to-Projected-FCF | 1.19 | |||||
| Price-to-DCF (Earnings Based) | 0.56 | |||||
| Price-to-DCF (FCF Based) | 0.84 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.5 | |||||
| Price-to-Graham-Number | 1.51 | |||||
| Price-to-Net-Current-Asset-Value | 7.41 | |||||
| Price-to-Net-Cash | 49.47 | |||||
| Earnings Yield (Greenblatt) % | 6.64 | |||||
| FCF Yield % | 4 | |||||
| Forward Rate of Return (Yacktman) % | 15.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regeneron Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12,690.26 | ||
| EPS (TTM) (€) | 37.039 | ||
| Beta | -0.01 | ||
| Volatility % | 30.4 | ||
| 14-Day RSI | 26.3 | ||
| 14-Day ATR (€) | 13.29287 | ||
| 20-Day SMA (€) | 743.62 | ||
| 12-1 Month Momentum % | 18.49 | ||
| 52-Week Range (€) | 700 - 1091.5 | ||
| Shares Outstanding (Mil) | 109.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regeneron Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regeneron Pharmaceuticals Inc Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc(WBO:REGN)'s stock price today?
The current price of WBO:REGN is €715.40. The 52 week high of WBO:REGN is €1091.50 and 52 week low is €700.00.
When is next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN) is 2025-01-31 Est..
Does Regeneron Pharmaceuticals Inc(WBO:REGN) pay dividends? If so, how much?
Regeneron Pharmaceuticals Inc(WBO:REGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers